Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which have proven cardiovascular benefits, are recommended in people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). However, there is limited real-world evidence comparing the effects of once-weekly (O...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Xi, Liang, Yuanjie, Rajpura, Jigar R., Yedigarova, Larisa, Noone, Josh, Xie, Lin, Inzucchi, Silvio, de Havenon, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662529/
https://www.ncbi.nlm.nih.gov/pubmed/37985992
http://dx.doi.org/10.1186/s12933-023-02051-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662529/
https://www.ncbi.nlm.nih.gov/pubmed/37985992
http://dx.doi.org/10.1186/s12933-023-02051-8

Ejemplares similares